Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

We recently published a list of 10 Stocks Insiders Are Selling In March. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other stocks ...

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...

Schroder Investment Management Group lowered its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 60.1% in the ...

Throughout the last three months, 14 analysts have evaluated Blueprint Medicines (NASDAQ:BPMC), offering a diverse set of opinions from bullish to bearish. The following table summarizes their ...

Learn more about whether Blueprint Medicines Corporation or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Shares of Blueprint Medicines stock opened at $89.59 on Tuesday. Blueprint Medicines has a 52-week low of $80.68 and a 52-week high of $121.90. The stock has a market capitalization of $5.73 ...

Morgan Stanley analyst Judah Frommer assumed coverage of Blueprint Medicines (BPMC) with an Equal Weight rating and price target of $100, down ...

Blueprint Medicines Corporation (NASDAQ:BPMC), a commercial-stage biotech firm with a market capitalization of $5.8 billion specializing in precision therapies for rare diseases, has been making ...

In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other stocks Insiders are selling in March. Wall Street experienced a challenging ...